Palatin Technologies Inc. (PTN)

May 27, 2025

Palatin Technologies (PALI) Teams Up with Key Managers for Inves - GuruFocus

May 27, 2025

May 27, 2025

Palatin Technologies (PALI) Teams Up with Key Managers for Investment Strategy | PALI Stock News - GuruFocus

May 27, 2025

May 25, 2025

Palatin Technologies, Inc. (AMEX:PTN) Q3 2025 Earnings Call Transcript - MSN

May 25, 2025

May 20, 2025

Palatin Technologies (NYSE:PTN) Coverage Initiated by Analysts at StockNews.com - Defense World

May 20, 2025

May 15, 2025

Moderate Dry Eye Market Growth to Accelerate in Forecast Period (2023-2032), DelveInsight Analyzes | mc2 therapeutics, Palatin Technologies, Novaliq - The Globe and Mail

May 15, 2025

May 15, 2025

Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update - The Malaysian Reserve

May 15, 2025

May 15, 2025

Palatin Technologies Inc (PTNT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance

May 15, 2025

May 15, 2025

Palatin Technologies Reports Q3 2025 Earnings and Updates - TipRanks

May 15, 2025

May 15, 2025

Palatin Technologies Inc (PTNT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus

May 15, 2025

May 14, 2025

Earnings call transcript: Palatin’s Q3 FY2025 shows narrower loss By Investing.com - Investing.com Nigeria

May 14, 2025

May 14, 2025

Earnings call transcript: Palatin’s Q3 FY2025 shows narrower loss - Investing.com Australia

May 14, 2025

May 14, 2025

Palatin Technologies Q1 Net Loss Narrows On Lower Expenses - Nasdaq

May 14, 2025

May 14, 2025

Palatin Technologies (PTN) to Release Quarterly Earnings on Wednesday - Defense World

May 14, 2025

May 12, 2025

Palatin Technologies director Robert DeVeer buys $10,180 in stock By Investing.com - Investing.com Nigeria

May 12, 2025

May 12, 2025

Palatin Technologies director Robert DeVeer buys $10,180 in stock - Investing.com

May 12, 2025

May 10, 2025

Palatin reveals potential diabetic retinopathy treatments - Investing.com

May 10, 2025

May 10, 2025

Palatin reveals potential diabetic retinopathy treatments By Investing.com - Investing.com India

May 10, 2025

May 09, 2025

Palatin Unveils Promising Preclinical Data For Diabetic Retinopathy Treatments At ARVO 2025 - Nasdaq

May 09, 2025

May 09, 2025

Palatin Technologies Announces Closing of Reduced Public Offerin - GuruFocus

May 09, 2025

May 09, 2025

Two new option listings and two option delistings on May 9th - TipRanks

May 09, 2025

May 09, 2025

Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025 - GuruFocus

May 09, 2025

May 09, 2025

Palatin expects $11.5M financing to cure NYSE American delisting notice - MSN

May 09, 2025

May 09, 2025

Palatin Technologies Announces Closing of Reduced Public Offering - Morningstar

May 09, 2025

May 08, 2025

Palatin Technologies Announces Closing of Reduced Public Offering | PTN Stock News - GuruFocus

May 08, 2025

May 08, 2025

Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025 - The Malaysian Reserve

May 08, 2025

May 08, 2025

Palatin Technologies (PTN) Reveals Promising Phase 3 Study Results for PL9643 in Dry Eye Disease | PTN Stock News - GuruFocus

May 08, 2025

May 08, 2025

Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025 | PTN Stock News - GuruFocus

May 08, 2025

May 08, 2025

PTN Faces Delisting from NYSE American, Shares Transition to OTC Market | PTN Stock News - GuruFocus

May 08, 2025

May 08, 2025

Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice - Lelezard

May 08, 2025

May 07, 2025

Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice | PTN Stock News - GuruFocus

May 07, 2025

May 07, 2025

Palatin Technologies faces delisting from NYSE American due to low stock price - Investing.com Nigeria

May 07, 2025

May 07, 2025

NYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN) - Business Wire

May 07, 2025

May 07, 2025

Palatin secures $11.5 million to tackle NYSE delisting, boost obesity drugs - Investing.com Australia

May 07, 2025

May 07, 2025

Palatin Technologies sets terms for $23 million offering By Investing.com - Investing.com South Africa

May 07, 2025

May 07, 2025

Palatin secures $11.5 million to tackle NYSE delisting, boost obesity drugs By Investing.com - Investing.com South Africa

May 07, 2025

May 07, 2025

Palatin Prices $11.5 Mln Public Offering - Nasdaq

May 07, 2025

May 07, 2025

Palatin Expects $11.5 Mln Offering To Aid NYSE Compliance And Fuel Obesity Drug Development - Nasdaq

May 07, 2025

May 07, 2025

Palatin (PTN) Aims to Address Delisting Concerns with Public Off - GuruFocus

May 07, 2025

May 07, 2025

Palatin Technologies Stock Trading Halted Pending Material Announcement - marketscreener.com

May 07, 2025

May 07, 2025

Palatin Expects $11.5 Million Financing to Cure NYSE American De - GuruFocus

May 07, 2025

May 07, 2025

Palatin Expects $11.5 Million Financing - citybiz

May 07, 2025

May 07, 2025

Palatin Technologies Announces Pricing Of Up To $23 Million Public Offering - marketscreener.com

May 07, 2025

May 07, 2025

Palatin Technologies Announces Pricing of up to $23 Million Public Offering - GuruFocus

May 07, 2025

May 07, 2025

Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice - StreetInsider

May 07, 2025